NET SALES AS OF DECEMBER 31, 2017
Longjumeau, January 31, 2018
PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of December 31, 2017.
The PCAS Group had generated consolidated net sales of €218.3 million as of December 31, 2017, representing growth of +13.7% compared to the same period of the previous financial year.
| In millions of euros | 2017 | 2016 | % change | |||
| Net sales as of 31 December | 218.3 | 192.0 | 13.7% | |||
| Pharmaceutical Synthesis | 148.9 | 130.0 | 14.6% | |||
| Fine Specialty Chemicals | 69.3 | 62.0 | 11.8% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business generated €148.9 million, up 14.6% on 2016, which was especially driven by the Exclusive activity.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled €69.3 million, up 11.8% on 2016, with growth in both Performance Additives and Advanced Specialty Chemicals, more particularly for the micro-electronics part.
| NEXT FINANCIAL DISCLOSURE: | |
| 2017 results, February 20, 2018 |
ABOUT PCAS
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.
To find out more about PCAS, visit: www.pcas.com
| PCAS | NewCap |
| Vincent Touraille / Eric Moissenot PCAS | Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial communication and Investor Relations |
| Tel. : +33 1 69 79 61 32 www.pcas.com | Tel. : +33 1 44 71 98 53 pcas@newcap.eu |
